home > news > detailed info

Charles River Laboratories Continues Commitment to Oncology Drug Discovery

Charles River

Team of oncology experts expand data in Tumor Model Compendium and present strong portfolio at industry conferences

Charles River Laboratories International, Inc. (NYSE: CRL) today announced new additions to the Tumor Model Compendium. Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research.

The most recent Compendium update adds gastric and liver models, as well as new molecular data for leukemia, liver cancer, lymphoma, breast cancer and ovarian cancer. The newest additions to the Compendium provide oncology researchers access to data that allows them to identify the most appropriate tumor models, leading to a more targeted study design from the start, saving time and money on the path to the clinic.

The Compendium includes tumor models from a wide range of tumor subtypes for both in vivo and in vitro oncology research, including patient-derived xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic models.

Presence at Scientific Conferences

The Compendium is just one example of Charles River’s commitment to oncology research. Charles River experts presented four posters at the Society for Immunotherapy’s (SITC) 33rd Annual Meeting and will present nine posters at the European Organisation for Research and Treatment of Cancer (EORTC) Conference in Dublin, Ireland.

Noteworthy posters include:

  • Modulation of adenosine levels in the tumor microenvironment following treatment with anti-PD1 antibodies and oxaliplatin: an in vivo microdialysis study (Presented at SITC’s 33rd Annual Meeting by Arash Rassoulpour) Utilizing in vivo microdialysis, a technique that has been prominent in neuroscience research for over 50 years, Charles River researchers monitored oncometabolites and immunomodulators directly in the tumor microenvironment.
  • Development of a disseminated AML mouse model to evaluate the therapeutic activity of immune checkpoint inhibitors using bioluminescence imaging (To be presented at EORTC by David Harris) Charles River researchers developed a disseminated AML disease model to evaluate the therapeutic response to immune checkpoint inhibitors, PD-1, PD-L1 and CTLA-4.
A full schedule of Charles River’s activities during SITC’s 33rd Annual Meeting and EORTC is available online, with poster reprint available after the conferences. Reprints of posters presented at EORTC will also be available in booth A2 during the show.

Approved Quotes

  •  “The power of our oncology portfolio is stronger than ever. Our scientists have worked diligently to accelerate cancer research and anticancer drug development efforts so patients can get the treatments they desperately need.” –Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Charles River
  • “Since its inception, our Tumor Model Compendium has made finding the best research model for oncology research easier. We are excited about the latest additions and are proud to offer this important resource to oncology researchers.” –Julia Schueler, Research Director, Charles River

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit

View source version on

Source: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

Investor Contact:
Todd Spencer, 781-222-6455
Corporate Vice President, Investor Relations
Media Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
phone +1.877.CRIVER.1
email Charles River Laboratories International, Inc. 251 Ballardvale Street Wilmington, MA 01887
Print this page
Send to a friend
News and Press Releases

Sartorius debuts the Intellicyt iQue3 at CYTO® 2019

Sartorius will be showcasing the latest addition to its cellular analysis portfolio on booth #103 at this year’s CYTO® conference and exhibition, with the launch of the Intellicyt iQue3. The event – which takes place in Vancouver, Canada, from June 22 to 26 – will give delegates the chance to explore a smarter way to perform flow cytometry experiments.
More info >>

White Papers

Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.


Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >>

Industry Events

Clinical Innovation Partnerships

11-12 September 2019, Hotel Palace, Berlin

Clinical Innovation Partnerships is the only event for senior clinical operations and procurement professionals driving innovation in their clinical trials. It is where the pharma, CRO and vendor clinical trials ecosystem meet to drive innovation in digitalisation, tech and partnering to improve patient experience and reduce trial cost and time.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement